Multimodal Pathology Patents: Leaders, Trends & White Space 2026
Multimodal Pathology and Molecular Prediction Patents
One filer leads a fragmented field. the leading assignee holds 14 records against a fifth-place count of 5 and a tenth-place count of 1, in a ranked list of 19 companies. Filings ran from 0 in 2017 to a peak of 13 in 2020, then declined; the 2021-to-2024 span shows a -100% change (5 records down to 0), and 2024 is the most recent year that can be read as complete. 2025 and 2026 figures are still arriving and should not be read as a continued decline.
- 1CARIS MPI INC14
- 2INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)5
- 3UNIV RENE DESCARTES PARIS V5
- 4INTEGRAGEN5
- 5VERILY LIFE SCIENCES LLC5
See the full multimodal pathology and molecular prediction analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in multimodal pathology and molecular prediction?
One assignee leads the ranked list of 19 companies with 14 records, well ahead of the fifth-place holder at 5 and the tenth-place holder at 1. This gap suggests an early, sustained filing position rather than a crowded multi-way race. The rest of the field is a long tail of firms and institutions with only a handful of filings each, so a freedom-to-operate review should weight the leader’s portfolio heavily and treat the rest as case-by-case checks.
Is patent filing in this field growing or shrinking?
Filing activity peaked at 13 records in 2020 and has not returned to that level; from 2021 to 2024 it fell -100%, from 5 records down to zero. However, 2024 is the most recent year that can be treated as complete because publication typically lags filing by about 18 months, so 2025 and 2026 figures are still incomplete and should not be read as continued decline. A fair read is that the field cooled after 2020 rather than that it has stopped.
What technology areas do these patents cover?
The dataset skews heavily toward bioinformatics and healthcare informatics: G16B appears in 71.9% of the 32 records and G16H in 46.9%, with C12Q (enzyme and DNA measurement) close behind at 43.8%. AI-model computing (G06N) and general digital data processing (G06F) appear in a quarter and under a fifth of records respectively. Because a single record can carry multiple IPC classes, these percentages overlap rather than sum to 100%, so read them as indicators of where claim density is highest, not as a breakdown of the whole field.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Multimodal Pathology and Molecular Prediction covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.